Literature DB >> 7020711

Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins.

F R Appelbaum, A Fefer, M A Cheever, C D Buckner, P D Greenberg, H G Kaplan, R Storb, E D Thomas.   

Abstract

Eight patients with disseminated non-Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high-dose chemotherapy, a supralethal dose of total-body irradiation, and a bone marrow transplant from a normal identical twin. Seven patients experienced complete remission. Four of the seven patients (two with diffuse poorly differentiated lymphocytic lymphoma, one with composite lymphoma, and one with diffuse moderately well differentiated lymphocytic lymphoma) remain in complete unmaintained remission 12-126 mo from transplantation. One patient relapsed after 10 mo but was retreated and is alive in unmaintained complete remission 73 mo from transplantation. One patient died of Pseudomonas pneumonia while in complete remission and one patient relapsed and died of progressive lymphoma. These results demonstrate that intensive chemoradiotherapy and twin marrow transplantation can induce frequent and enduring remissions in patients with disseminated non-Hodgkin's lymphoma who have failed conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7020711

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  Bone marrow transplantation. Part II--autologous.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1990-01

2.  Phase-I-II study of high-dose melphalan and autologous marrow transplantation in adult patients with poor-risk non-Hodgkin's lymphomas.

Authors:  B Mascret; D Maraninchi; J A Gastaut; D Baume; G Sebahoun; C Lejeune; G Novakovitch; D Sainty; N Horchowski; N Tubiana
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Autologous bone marrow transplantation in metastatic breast cancer.

Authors:  P S Stewart
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.